Among these, CD33 is a widely studied target, and its antibody‒drug conjugate, gemtuzumab ozogamicin, was approved in 2017 for use in treating newly diagnosed and relapsed or refractory CD33-positive AML patients [80, 81]. Here, CD33 is linked to acute myeloid leukemia.